COMPLETEDPHASE3

Clinical Efficacy and Safety Evaluation of Irbesartan High and Amlodipine Combined Therapy in Essential Hypertension Patients

A Randomized, Double-blind, Multicenter, Placebo-control, Parallel Group Phase # Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined Therapy in Essential Hypertension Patients

NCT05475665•Handok Inc.

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate efficacy and safety of Irbesartan and Amlodipine combined therapy in patients with essential hypertension inadequately controlled on Irbesartan monotherapy

Eligibility

Age

19 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Patients who are 19 years or older on screening
•Signed informed consent
•Patients with Essential Hypertension
•Other inclusion applied

Exclusion Criteria

•Orthostatic hypotension with symptom
•Other exclusion applied

Locations (1)

Hanyang University Seoul Hospital

Seoul, South Korea

Key Dates

Start Date

July 14, 2022

Primary Completion Date

March 30, 2023

Completion Date

June 13, 2023

Last Updated

August 18, 2023

Enrollment

157

ACTUAL participants

Conditions

Essential Hypertension

Interventions

Irbesartan/Amlodipine

DRUG

Irbesartan

DRUG

Study of KK3910 in Healthy Volunteers and Patients With Essential Hypertension

NCT06823947

Healthy Volunteers Essential Hypertension

View study

ACTIVE_NOT_RECRUITING

Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With Hypertension

NCT06604897

Essential Hypertension

View study

COMPLETEDPHASE3

PHASE III, RANDOMIZED, ACTIVE-COMPARATOR CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF NIFEDIPINE 30MG EXTENDED-RELEASE IN ADULT PATIENTS DIAGNOSED WITH MILD OR MODERATE HYPERTENSION IN COLOMBIA.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 18, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

NCT07448506

High Blood Pressure (& [Essential Hypertension])

View study

COMPLETEDNA